Table 2.
Stratified Analysis of Ondansetron Utilization by Insurance
| Stratified by gender/female | ||||||||
|---|---|---|---|---|---|---|---|---|
| Insurance | Cases | % | Ondansetron | % | Odds | OR | [low | up] |
| Commercial | 57653 | 0.33 | 33127 | 0.57 | 1.35 | 1.00 | NA | NA |
| MEDICAID | 16689 | 0.10 | 7405 | 0.44 | 0.80 | 0.59 | 0.57 | 0.61 |
| Medicare | 25634 | 0.15 | 12795 | 0.50 | 1.00 | 0.74 | 0.72 | 0.76 |
| SELF | 683 | 0.00 | 398 | 0.58 | 1.40 | 1.03 | 0.89 | 1.20 |
| Stratified by gender/male | ||||||||
| Insurance | Cases | % | Ondansetron | % | Odds | OR | [low | up] |
|
| ||||||||
| Commercial | 37971 | 0.22 | 21736 | 0.57 | 1.34 | 1.00 | NA | NA |
| MEDICAID | 8816 | 0.05 | 3729 | 0.42 | 0.73 | 0.55 | 0.52 | 0.57 |
| Medicare | 24836 | 0.14 | 10758 | 0.43 | 0.76 | 0.57 | 0.55 | 0.59 |
| SELF | 851 | 0.00 | 503 | 0.59 | 1.45 | 1.08 | 0.94 | 1.24 |
| Stratified by anes_type/general | ||||||||
| Insurance | Cases | % | Ondansetron | % | Odds | OR | [low | up] |
|
| ||||||||
| Commercial | 67193 | 0.39 | 48450 | 0.72 | 2.58 | 1.00 | NA | NA |
| MEDICAID | 16101 | 0.09 | 9277 | 0.58 | 1.36 | 0.53 | 0.51 | 0.54 |
| Medicare | 37071 | 0.21 | 21984 | 0.59 | 1.46 | 0.56 | 0.55 | 0.58 |
| SELF | 1201 | 0.01 | 847 | 0.71 | 2.39 | 0.93 | 0.82 | 1.05 |
| Stratified by anes_type/neuroaxial | ||||||||
| Insurance | Cases | % | Ondansetron | % | Odds | OR | [low | up] |
|
| ||||||||
| Commercial | 16634 | 0.10 | 4569 | 0.27 | 0.38 | 1.00 | NA | NA |
| MEDICAID | 6307 | 0.04 | 1491 | 0.24 | 0.31 | 0.82 | 0.76 | 0.87 |
| Medicare | 2374 | 0.01 | 451 | 0.19 | 0.23 | 0.62 | 0.56 | 0.69 |
| SELF | 112 | 0.00 | 27 | 0.24 | 0.32 | 0.84 | 0.54 | 1.30 |
| Stratified by anes_type/regional | ||||||||
| Insurance | Cases | % | Ondansetron | % | Odds | OR | [low | up] |
|
| ||||||||
| Commercial | 964 | 0.01 | 244 | 0.25 | 0.34 | 1.00 | NA | NA |
| MEDICAID | 305 | 0.00 | 53 | 0.17 | 0.21 | 0.62 | 0.45 | 0.86 |
| Medicare | 1144 | 0.01 | 190 | 0.17 | 0.20 | 0.59 | 0.47 | 0.73 |
| SELF | 18 | 0.00 | 6 | 0.33 | 0.50 | 1.48 | 0.55 | 3.97 |
| Stratified by anes_type/MAC | ||||||||
| Insurance | Cases | % | Ondansetron | % | Odds | OR | [low | up] |
|
| ||||||||
| Commercial | 10827 | 0.06 | 1600 | 0.15 | 0.17 | 1.00 | NA | NA |
| MEDICAID | 2788 | 0.02 | 312 | 0.11 | 0.13 | 0.73 | 0.64 | 0.83 |
| Medicare | 9874 | 0.06 | 927 | 0.09 | 0.10 | 0.60 | 0.55 | 0.65 |
| SELF | 202 | 0.00 | 21 | 0.10 | 0.12 | 0.67 | 0.42 | 1.05 |
Table 2: The stratified analysis of ondansetron utilization is exemplified by gender and anesthesia type and shows the odds of antiemetic administration by insurance status for each stratum. The odds ratio (OR) compares the odds to the reference population with commercial insurance (with the upper and lower 95% confidence interval in the following two columns) and favors commercial insurance over medicaid and medicare in all strata in this NACOR dataset (n = 173133) with complete information on insurance and antiemetic utilization (p<0.01), reported by 4 institutions.